# US 2015/0148247 A1 · Methods and devices for tuberculosis diagnosis using biomarker profiles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148247 A1
- Document ID: US20150148247A1
- Status: Published application
- Kind: A1
- Application number: 14/402,727
- Filed: 2013-05-24
- Published: 2015-05-28
- Earliest claimed: 2012-05-24
- Assignees: The Broad Institute, Inc.; The General Hospital Corporati d/b/a Massachusetts General Hospital
- Applicants: The Broad Institute, Inc.; The General Hospital Corporation d/b/a Massachusetts General Hospital
- Inventors: Rushdy Ahmad; Michael Gillette; Steven A. Carr
- Web page: https://patentgrep.com/patent/US20150148247A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/5695: {Mycobacteria}
- G01N 33/6869: {Interleukin}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- G01N 2333/475: Assays involving growth factors
- G01N 2333/54: Interleukins [IL]
- G01N 2333/5412: IL-6
- G01N 2333/5421: IL-8
- G01N 2333/7155: for interleukins [IL]
- G01N 2800/26: Infectious diseases, e.g. generalised sepsis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to tuberculosis diagnostic methods and devices that measure particular biomarker profiles in subjects and identify a subject having tuberculosis based on such profiles.

## Claims

### Claim 1

A method comprising:
(a) measuring protein levels of three or more biomarkers in a biological sample from a subject, wherein the biomarkers are selected from
(i) a first group consisting of AAT, Fibrinogen, Haptoglobin, C3, beta-2-macroglobulin, CRP, ICAM-1, TIMP-1, TNFR2, IL-18, IL-1RA, IL-6, IL-8, TNF-alpha, and VEGF (“Group I biomarker”); and/or
(ii) a second group consisting of A2Macro, MMP-2, VCAM-1, IL-17, and SCF (“Group II biomarker”);
(b) comparing the Group I and/or Group II biomarker protein levels with control levels; and
(c) identifying a subject with tuberculosis based on
(i) Group I biomarker protein levels that are elevated in the biological sample compared to the control levels and/or
(ii) Group II biomarker protein levels that are reduced in the biological sample compared to the control levels.

### Claim 2 (depends on 1)

The method of claim 1, wherein the control levels are derived from tuberculosis-negative subjects having a persistent cough.

### Claim 3 (depends on 1)

The method of claim 1, wherein the control levels are pre-determined.

### Claim 4

A method comprising:
(a) measuring protein levels of three or more biomarkers in a biological sample from a subject, wherein the biomarkers are selected from
(i) a first group consisting of AAT, Fibrinogen, Haptoglobin, C3, beta-2-macroglobulin, CRP, ICAM-1, TIMP-1, TNFR2, IL-18, IL-1RA, IL-6, IL-8, TNF-alpha, and VEGF (“Group I biomarker”); and/or
(ii) a second group consisting of A2Macro, MMP-2, VCAM-1, IL-17, and SCF (“Group II biomarker”);
(b) identifying a subject with tuberculosis based on
(i) a Group I biomarker protein level that is above a pre-determined threshold, and/or
(ii) a Group II biomarker protein level that is below a pre-determined threshold.

### Claim 5 (depends on 4)

The method of claim 4, wherein the pre-determined threshold is a Group I or a Group II biomarker protein level from tuberculosis-negative subjects having a persistent cough.

### Claim 6 (depends on 1)

The method of claim 1, wherein the three or more biomarkers are Group I biomarkers.

### Claim 7 (depends on 1)

The method of claim 1, wherein the three or more biomarkers are Group II biomarkers.

### Claim 8 (depends on 1)

The method of claim 1, wherein the three or more biomarkers are a combination of Group I biomarkers and Group II biomarkers.

### Claim 9 (depends on 1)

The method of claim 1, wherein the three or more biomarkers are selected from the group consisting of IL-18, IL-1RA, IL-6, IL-8, and VEGF.

### Claim 10 (depends on 1)

The method of claim 1, wherein the three or more biomarkers are selected from the group consisting of IL-18, IL-6, IL-8, and VEGF.

### Claim 11 (depends on 1)

The method of claim 1, wherein the biological sample is a blood or serum sample.

### Claim 12 (depends on 1)

The method of claim 1, wherein the tuberculosis is active tuberculosis.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject has a persistent cough.

### Claim 14 (depends on 1)

The method of claim 1, wherein the subject is HIV-negative.

### Claim 15 (depends on 1)

The method of claim 1, wherein the subject is an adult.

### Claim 16 (depends on 1)

The method of claim 1, wherein the protein levels are measured by an immuno-based assay.

### Claim 17 (depends on 1)

The method of claim 1, wherein the three or more biomarkers are four biomarkers.

### Claim 18 (depends on 1)

The method of claim 1, wherein the three or more biomarkers are five biomarkers.

### Claim 19

(canceled)

### Claim 20

A method comprising:
(a) measuring protein levels of three or more biomarkers in a biological sample from a subject, wherein the biomarkers are selected from the group consisting of
(i) a first group consisting of AAT, Fibrinogen, Haptoglobin, C3, beta-2-macroglobulin, CRP, ICAM-1, TIMP-1, TNFR2, IL-18, IL-1RA, IL-6, IL-8, TNF-alpha, and VEGF (“Group I biomarker”); and/or
(ii) a second group consisting of A2Macro, MMP-2, VCAM-1, IL-17, and SCF (“Group II biomarker”); and
(b) identifying a subject with tuberculosis based on
(i) a Group I biomarker protein level that is above a pre-determined threshold, and/or
(ii) a Group II biomarker protein level that is below a pre-determined threshold, wherein the predetermined thresholds are set to yield a specificity greater than 50% and/or a sensitivity greater than 50%.

### Claim at position 21

21-24. (canceled)

### Claim 25

A device comprising
a sample inlet and
binding partners for three or more biomarkers selected from the group consisting of
(i) a first group consisting of AAT, Fibrinogen, Haptoglobin, C3, beta-2-macroglobulin, CRP, ICAM-1, TIMP-1, TNFR2, IL-18, IL-1RA, IL-6, IL-8, TNF-alpha, and VEGF (“Group I biomarker”), and/or
(ii) a second group consisting of A2Macro, MMP-2, VCAM-1, IL-17, and SCF (“Group II biomarker”),
wherein the binding partners are grouped together on a substrate based on biomarker specificity and groups are physically separated from each other on the substrate.

### Claim at position 23

26-36. (canceled)
